Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes

Autor: Ercan Tuncel, Emine Kirhan, Sinem Kiyici, Hakan Yorulmaz, Canan Ersoy, Emre Sarandol, Cuma Bulent Gul, Deniz Sigirli, Erdinc Erturk, Sazi Imamoglu, Ozen Oz, Oguz Kaan Unal, Soner Cander
Přispěvatelé: YORULMAZ, HAKAN, Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı., Gül, Özen Öz, Kıyıcı, Sinem Kücçuüksaraç, Ersoy, Canan, Cander, Soner, Yorulmaz, Hakan, Gül, Cuma Bülent, Sarandöl, Emre, Kırhan, Emine, Sığırlı, Deniz, Ertürk, Erdinç, Tuncel, Ercan, İmamoğlu, Sazi, Ünal, Oğuz Kağan, AAI-1005-2021, A-7063-2018, AAJ-6536-2021, AAA-7472-2021, ABE-1716-2020, AAH-8861-2021
Rok vydání: 2011
Předmět:
Blood Glucose
Male
Time Factors
Turkey
Circulating ghrelin
Endocrinology
Diabetes and Metabolism
Glucose blood level
Type 2 diabetes
Treatment response
Body Mass Index
Endocrinology
Diabetes mellitus type 2
Incretin-based therapies
Endocrinology & metabolism
Biological markers
Stomach
General Medicine
Middle Aged
Lipids
Metformin
Ghrelin
Postprandial
Treatment Outcome
Body mass
Randomized controlled trial
Sitagliptin
Pyrazines
Peptide
Diabetes control
Female
medicine.symptom
medicine.drug
Human
Adult
medicine.medical_specialty
Inhibitor
Clinical article
Hemoglobin a
glycosylated
Down-Regulation
Article
Sitagliptin Phosphate
Insulin resistance
Internal medicine
Diabetes mellitus
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Weight-gain
Aged
Glycated Hemoglobin
Analysis of Variance
Dipeptidyl-Peptidase IV Inhibitors
Chi-Square Distribution
business.industry
Diet therapy
Body Weight
Glycosylated hemoglobin
Dipeptidyl Peptidase IV Inhibitor
Non Insulin Dependent Diabetes Mellitus
Sulfonylurea
Triazoles
medicine.disease
Monotherapy
Lipid blood level
Diabetes Mellitus
Type 2
Insulin therapy
Non insulin dependent diabetes mellitus
business
Hormone blood level
Weight gain
Controlled study
Biomarkers
Zdroj: Diabetes research and clinical practice. 94(2)
ISSN: 1872-8227
Popis: Aim Sitagliptin is not associated with weight gain and has neutral effects on body weight. It is unclear whether sitagliptin treatment alters serum ghrelin levels in people with type 2 diabetes. Methods Forty-four subjects with type 2 diabetes were randomly assigned to receive sitagliptin or medical nutrition therapy (MNT) for 12 weeks. Changes in anthropometric variables, glycemic control, insulin resistance, lipid parameters, and total ghrelin levels were evaluated at baseline and following 12 weeks of treatment. Results Significant decreases in body weight and body mass index were observed over the entire study period in both treatment groups. Glycosylated hemoglobin and postprandial plasma glucose levels were statistically significant decreased in the groups receiving sitagliptin compared with baseline values ( p = 0.021 and p = 0.021, respectively), while they were unchanged in the groups receiving MNT. There was a significant decrease in total ghrelin in the groups receiving sitagliptin ( p = 0.04) compared with baseline values but not in the groups receiving MNT ( p = 0.46) at the end of the 12 weeks. Conclusions In this study of patients with type 2 diabetes, treatment with sitagliptin was associated with a significant decrease in serum ghrelin levels. These results suggest that the neutral effect of sitagliptin on weight might be associated with the suppression of fasting serum ghrelin levels.
Databáze: OpenAIRE
Externí odkaz: